Richard T Clements1, Brenda Cordeiro, Jun Feng, Cesario Bianchi, Frank W Sellke. 1. Cardiovascular Research Center, Department of Surgery, Rhode Island Hospital and Alpert Medical School, Brown University, Coro 5.230, 1 Hoppin St, Providence, RI 02903, USA. rclements2@lifespan.org
Abstract
BACKGROUND: Cardioplegia and cardiopulmonary bypass (CP/CPB) subjects myocardium to complex injurious stimuli that can result in cardiomyocyte and vascular contractile abnormalities. Rottlerin, originally identified as a delta-protein kinase C inhibitor, has a number of known additional effects that may be beneficial in the setting of CP/CPB. We tested the hypothesis that rottlerin mitigates deleterious effects associated with CP/CPB. METHODS AND RESULTS: Langendorff-perfused isolated rat hearts were subjected to 2 hours intermittent cold (10°C) CP (St Thomas II) followed by 30 minutes normothermic reperfusion. CP was delivered every 30 minutes for 1 minute. Hearts were treated with rottlerin 1 μmol/L (CP+R) (n=7) or without rottlerin (CP) (n=9), and the BK(Ca++) channel inhibitor paxilline 100 nmol/L was supplied in the CP. Hearts constantly perfused with KHB served as controls (n=6). Baseline parameters of cardiac function were similar between groups. CP resulted in reduced cardiac function (left ventricular diastolic pressure, 39 ± 3.8%; ± dP/dt, 32 ± 4.4%, -41 ± 5.1% decrease compared to baseline). Treatment with rottlerin 1 μmol/L significantly improved CP-induced cardiac function (left ventricular diastolic pressure, 20 ± 5.9%; ± dP/dt, 5.2 ± 4.5%, -11.6 ± 4.7% decrease versus baseline; P<0.05 CP+R versus CP). Rottlerin also caused a significant increase in coronary flow postreperfusion (CP, 34 ± 4.2% decrease from baseline; CP+R, 26 ± 9.6% increase over baseline; P=0.01). Independent of vascular effects, CP significantly decreased isolated myocyte contraction, which was restored by rottlerin treatment. The BK(Ca++) channel inhibitor greatly reduced the majority of beneficial effects associated with rottlerin. CONCLUSIONS: Rottlerin significantly improves cardiac performance after CP arrest through improved cardiomyocyte contraction and coronary perfusion.
BACKGROUND: Cardioplegia and cardiopulmonary bypass (CP/CPB) subjects myocardium to complex injurious stimuli that can result in cardiomyocyte and vascular contractile abnormalities. Rottlerin, originally identified as a delta-protein kinase C inhibitor, has a number of known additional effects that may be beneficial in the setting of CP/CPB. We tested the hypothesis that rottlerin mitigates deleterious effects associated with CP/CPB. METHODS AND RESULTS: Langendorff-perfused isolated rat hearts were subjected to 2 hours intermittent cold (10°C) CP (St Thomas II) followed by 30 minutes normothermic reperfusion. CP was delivered every 30 minutes for 1 minute. Hearts were treated with rottlerin 1 μmol/L (CP+R) (n=7) or without rottlerin (CP) (n=9), and the BK(Ca++) channel inhibitor paxilline 100 nmol/L was supplied in the CP. Hearts constantly perfused with KHB served as controls (n=6). Baseline parameters of cardiac function were similar between groups. CP resulted in reduced cardiac function (left ventricular diastolic pressure, 39 ± 3.8%; ± dP/dt, 32 ± 4.4%, -41 ± 5.1% decrease compared to baseline). Treatment with rottlerin 1 μmol/L significantly improved CP-induced cardiac function (left ventricular diastolic pressure, 20 ± 5.9%; ± dP/dt, 5.2 ± 4.5%, -11.6 ± 4.7% decrease versus baseline; P<0.05 CP+R versus CP). Rottlerin also caused a significant increase in coronary flow postreperfusion (CP, 34 ± 4.2% decrease from baseline; CP+R, 26 ± 9.6% increase over baseline; P=0.01). Independent of vascular effects, CP significantly decreased isolated myocyte contraction, which was restored by rottlerin treatment. The BK(Ca++) channel inhibitor greatly reduced the majority of beneficial effects associated with rottlerin. CONCLUSIONS:Rottlerin significantly improves cardiac performance after CP arrest through improved cardiomyocyte contraction and coronary perfusion.
Authors: Jun Feng; Yuhong Liu; Richard T Clements; Neel R Sodha; Kamal R Khabbaz; Venkatachalam Senthilnathan; Katherine K Nishimura; Seth L Alper; Frank W Sellke Journal: Circulation Date: 2008-09-30 Impact factor: 29.690
Authors: Richard T Clements; Neel R Sodha; Jun Feng; Shigetoshi Mieno; Munir Boodhwani; Basel Ramlawi; Cesario Bianchi; Frank W Sellke Journal: J Thorac Cardiovasc Surg Date: 2007-12 Impact factor: 5.209
Authors: André Heinen; Mohammed Aldakkak; David F Stowe; Samhita S Rhodes; Matthias L Riess; Srinivasan G Varadarajan; Amadou K S Camara Journal: Am J Physiol Heart Circ Physiol Date: 2007-05-18 Impact factor: 4.733
Authors: Ehtesham Shafique; Anali Torina; Karla Reichert; Bonnie Colantuono; Nasifa Nur; Khawaja Zeeshan; Vani Ravichandran; Yuhong Liu; Jun Feng; Khawaja Zeeshan; Laura E Benjamin; Kaikobad Irani; Elizabeth O Harrington; Frank W Sellke; Md Ruhul Abid Journal: Cardiovasc Res Date: 2017-01-14 Impact factor: 10.787